CureVac appoints oncologist and drug development expert Dr. Mehdi Shahidi to supervisory board
TÜBINGEN, Germany/BOSTON, United States – August 15, 2024 – CureVac N. V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company introducing a new generation of transformative messenger ribonucleic acid (“mRNA”) medicines, has appointed Mehdi Shahidi, clinical oncologist, M. D. , as an independent director of the company’s Supervisory Board. Shahidi replaces Ralf Clemens, who served on the Supervisory Board from March 2016 to September 2023.
“Dr. Shahidi represents a vital addition to CureVac’s board of directors as we develop our technological innovation and research and development, and especially as we move forward in establishing the clinical foundation for a new generation of mRNA-based cancer vaccines. “stated Jean Stéphenne, Chairman of CureVac’s Supervisory Board, “With his extensive experience in bringing cutting-edge cure applicants to the clinic and moving toward approval, Dr. Shahidi will be an invaluable asset to our team. “
Dr. Shahidi’s appointment is effective at CureVac SE effective early September 2024, and his related appointment with CureVac N. V. It will be held at the next Annual General Meeting in June 2025.
For more information, please see the Company’s reports and filings with the U. S. Securities and Exchange Commission (SEC). You can download those documents by visiting EDGAR at the SEC at www. sec. gov.